Thyrocare Q1 FY27 results: Revenue up 26%, PAT up 39% YoY
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts more than Nifty Microcap 250 and 3.9 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare Technologies posted Q1 FY27 standalone revenue of Rs 225.66 Cr, up 26.1% YoY from Rs 178.89 Cr. Standalone PAT rose 39.2% to Rs 50.17 Cr from Rs 36.05 Cr. EPS at Rs 3.15 versus Rs 2.27 restated. Consolidated revenue grew 24.3% to Rs 240.02 Cr with PAT up 34.1% at Rs 51.33 Cr. Diagnostic testing segment drove growth at about 27%. Price Waterhouse issued unmodified review. Ernst and Young reappointed internal auditor for FY27.
Strong double-digit growth in revenue and profit likely positive for stock sentiment; clean audit opinion supports confidence.